Roche antimalaria drug
Executive Summary
FDA approved orphan drug Larium (mefloquine) May 2 for treatment and prevention of two resistant strains of malaria. The 250 mg oral tablets, which will be available in three to six months, are indicated for infections with two parasites, Plasmodium falciparum (including those resistant to other antimalarials) and Plasmodium vivax. The U.S. Army's Walter Reed Institute invented the compound. Development and testing was conducted by both the Army and Roche; both have NDAs, but Roche will be the sole manufacturer. It has been approved in 11 other countries.
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: